XClose

UCL Cancer Institute

Home
Menu

Research Profile Prof Gerhardt Attard

Professor Gerhardt Attard MD PhD FRCP

Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He holds an advanced Cancer Research UK Clinician Scientist award and is Team Leader of the Treatment Resistance Group at the UCL Cancer Institute. 

He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 130 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. 

Prof Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investigator Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. He received the Cancer Research UK Future Leader Award in 2017.  Prof Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.


Opportunities at Attard Lab: 

Research Fellow - Computational Biology

Focusing on interpreting genomic, epigenomic and transcriptomic data from plasma samples and tumours from clinically-relevant prostate cancer cohorts with carefully annotated clinical follow-up data collected in prospective randomised clinical trials.

Deadline: 10 April 2019

Cancer Research UK Clinical Training Fellow

The project and candidate will initially focus on generating and integrating genomic, epigenomic and transcriptomic data from plasma samples from clinically-relevant prostate cancer cohorts with carefully annotated clinical follow-up data. Thereafter, the ambition is for  the prospective evaluation of the PRIME test in a clinical trial.

Deadline: 28 March 2019